TTK and ovarian serous carcinoma: CFI-402257 (Treadwell Therapeutics) is a recently developed inhibitor of the TTK serine/threonine kinase (also known as MPS1), a member of the previously discussed SAC, that has shown promise in suppressing spindle checkpoint activity and subsequently cancerous proliferation as part of combination therapy in a variety of tumors, including patient-derived cultures of hepatocellular carcinoma [105] and serous ovarian carcinoma [106].